Lead Product(s) : IMO-8400
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
July 15, 2013
Lead Product(s) : IMO-8400
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IMO-3100
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 19, 2012
Lead Product(s) : IMO-3100
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable